China approves use of Cuban drug to treat pancreatic cancer
Nimotuzumab, a medicine developed by Cuba’s Center for Molecular Immunology (CIM), was approved in China for the treatment of pancreatic cancer, after a phase III clinical study.
Radio Ciudad del Mar, desde Cienfuegos, Cuba
Radio Ciudad del Mar, productora de contenidos para la Radio e Internet, desde Cienfuegos, Cuba
🎧 Escúchenos en audio real
Nimotuzumab, a medicine developed by Cuba’s Center for Molecular Immunology (CIM), was approved in China for the treatment of pancreatic cancer, after a phase III clinical study.